Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 4Hodgkin Disease 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Bronchiolitis Obliterans Syndrome 1

Interventions

fludarabine 8ibrutinib 7fludarabine phosphate 7Cyclophosphamide 6Busulfan 6Whole-Body Irradiation 4Tacrolimus 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Methotrexate 3Mesna 3Lenalidomide 3Bone Marrow Transplantation 3Bendamustine Hydrochloride 3thymoglobulin 2pirtobrutinib 2blinatumomab 2Vincristine 2Patient Reported Outcome Measures 2Doxorubicin 2Biopsy 2Behavior Therapy 2venetoclax 1sargramostim 1romiplostim 1pegylated granulocyte colony-stimulating factor 1pegaspargase 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphoid × mocetinostat × Lymphoid × Clear all
NCT00431873 2015-07-01

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Mirati Therapeutics Inc.

Phase 2 Completed
21 enrolled
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡